REPL Replimune Group, Inc.

Mentions (20)

• Newsglobenewswire.com·1d ago·Neutral

  REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm NEW YORK, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL).

  View source ↗
• Newsglobenewswire.com·1d ago·Negative

  Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit LOS ANGELES, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL) securities between O…

  View source ↗
• Newsglobenewswire.com·1d ago·Neutral

  …ted financing extends cash runway to support commercial launch and confirmatory trial WOBURN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2026 and provided a business update.

  View source ↗
• Newsbusinesswire.com·1d ago·Negative

  INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - REPL SAN DIEGO--(BUSINESS WIRE)---- $REPL #REPL--The case alleges Replimune and certain of its executives made false and/or misleading statements to investors.

  View source ↗
• Newsglobenewswire.com·1d ago·Negative

  REPL SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Replimune Group, Inc. Investors - Contact Kirby McInerney LLP by October 5, 2026 NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securitie…

  View source ↗
• Newsprnewswire.com·2d ago·Negative

  SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated the study design concerns it had previously communicated were never addressed, and REPL shares fell to $1.70. NEW YORK, Aug. 13, 2026 /PRNewswire/ -- SueWallSt reminds purchasers o…

  View source ↗
• Newsprnewswire.com·2d ago·Neutral

  …ewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Replimune securities between October 20, 2025 and April 10, 2026, both dates inclusive (the "Class Period").

  View source ↗
• Newsbusinesswire.com·2d ago·Negative

  REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP reminds purchasers of Replimune Group, Inc. (NASDAQ: REPL) securities of a pending securities class action on behalf of shareholders who purchased between October 20, 2025 and April 10, 2026. See if you could be eligible to recover. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.…

  View source ↗
• Newsglobenewswire.com·2d ago·Neutral

  REPL Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Replimune Group, Inc. Securities Class Action Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1

  View source ↗
• Newsprnewswire.com·3d ago·Neutral

  Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL Important Information Regarding Section 20(a) Individual Liability Claims: CEO Sushil Patel and CFO Emily Hill are named as individual defendants in a securities class action alleging Replimune's RP1 disclosures omitted unresolved FDA study-design concerns. NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Replimune

  View source ↗
• Newsglobenewswire.com·3d ago·Negative

  REPL INVESTOR NOTICE: Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead the Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026, inclusive (the “Class Period”), have until October 5, 2026 to seek appointment as lead

  View source ↗
• Newsglobenewswire.com·3d ago·Neutral

  INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who in

  View source ↗
• Newsprnewswire.com·3d ago·Negative

  Replimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit LOS ANGELES, Aug. 11, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Replimune Group, Inc. (REPL) have opportunity to lead the securities fraud class action lawsuit.

  View source ↗
• Newsnewsfilecorp.com·4d ago·Neutral

  Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - August 11, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities la

  View source ↗
• Newsbusinesswire.com·4d ago·Neutral

  REPL INVESTOR ALERT: Securities Class Action Filed Against Replimune Group, Inc. – Investors Encouraged to Contact Kirby McInerney LLP NEW YORK--(BUSINESS WIRE)---- $REPL #ClassAction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) common stock between October 20, 2025 and April 10, 2026, inclusive (“the Class Period”). If you suffered a loss on your R

  View source ↗
• Newsprnewswire.com·4d ago·Negative

  REPL INVESTOR ALERT: Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead the Replimune Class Action Lawsuit SAN DIEGO, Aug. 10, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP  announces that purchasers or acquirers of Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026, inclusive (the "Class Period"), have until October 5, 2026 to seek appointment as lead plaintiff of the Replimune class action lawsuit.  Captioned Toor v

  View source ↗
• Newszacks.com·5d ago·Positive

  Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months REPL's RP1 secures FDA approval for advanced melanoma, easing regulatory uncertainty. The company expands its oncolytic immunotherapy pipeline.

  View source ↗
• Newsprnewswire.com·5d ago·Neutral

  REPL Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Replimune Group, Inc. SAN DIEGO, Aug. 10, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 ("Class Period").  Replimune purports to be a clinical-stage bi

  View source ↗
• Newsbusinesswire.com·5d ago·Neutral

  Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REPL LOS ANGELES--(BUSINESS WIRE)---- $REPL--Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REPL.

  View source ↗
• Newsbusinesswire.com·7d ago·Negative

  REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $REPL--REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law.

  View source ↗